Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
Psych Congress Elevate
Las Vegas, NV | May 28 - 31, 2025
AXS-05 | Alzheimer’s Disease Agitation
Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
AXS-05 | Alzheimer’s Disease Agitation
Dr. George Grossberg, MD, describes the “Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study” poster
Major Depressive Disorder
Real-World Experience With Treatment and Expectations by Satisfaction Status of Persons With Major Depressive Disorder
AXS-05 | Major Depressive Disorder
Initiating Dextromethorphan 45 mg – Bupropion 105 mg in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations
AXS-05 | Major Depressive Disorder
Erin Crown – MHS, PA-C, Psych-CAQ – presents the “Initiating Dextromethorphan 45 mg – Bupropion 105 mg in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations” poster
AXS-05 | Major Depressive Disorder
Supplemental Information for “Initiating Dextromethorphan 45 mg – Bupropion 105 mg in Patients With Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations” – All Recommendations
